Insider Selling: Bristol Myers Squibb (NYSE:BMY) SVP Sells $33,750.00 in Stock

Bristol Myers Squibb Company (NYSE:BMY) SVP Phil Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bristol Myers Squibb Trading Down 0.4%

BMY traded down $0.24 during trading on Wednesday, hitting $67.68. 7,505,226 shares of the company’s stock were exchanged, compared to its average volume of 12,160,939. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The stock has a 50 day moving average price of $61.01 and a 200 day moving average price of $59.54. The firm has a market cap of $138.25 billion, a P/E ratio of 14.91, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm posted $1.46 EPS. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BMY shares. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Jefferies Financial Group cut shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Citigroup reaffirmed a “neutral” rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently added to or reduced their stakes in the company. Life Cycle Investment Partners Ltd bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $34,406,000. Lazard Asset Management LLC raised its holdings in Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the period. Axxcess Wealth Management LLC lifted its position in Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after acquiring an additional 21,196 shares during the last quarter. Callan Family Office LLC bought a new stake in Bristol Myers Squibb during the second quarter valued at about $3,575,000. Finally, BlackRock Inc. boosted its holdings in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.